Tag: Bruton’s tyrosine kinase (BTK) inhibitor

1. The Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib when compared to placebo treatment in multiple sclerosis patients showed the ability to reduce the number of gadolinium enhancing lesions on MRI imaging. 2. Key clinical outcomes of annualized relapse rates or change in a disability score were not different between patients...
1. The Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib when compared to placebo treatment in multiple sclerosis patients showed the ability to reduce the number of gadolinium enhancing lesions on MRI imaging. 2. Key clinical outcomes of annualized relapse rates or change in a disability score were not different between patients...